However, anti-PD-1 therapy in combination with ipilimumab may offer more benefit than anti-PD-1 monotherapy for certain patients, e.g., those with BRAF-mutant melanoma, liver or brain metastases, rare melanoma subtypes (e.g., mucosal, acral, uveal), high lactate dehydrogenase (LDH) or high tumour burden. Here, BRAF is linked to neoplasm.